6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings have informed clinical practice guidelines and policy, which now recommend that SMBG not be used routinely in this group (21–26).”
In the citing paper
“While the drug manufacturer is currently offering a savings card program for some patients for whom pricing is a barrier, payor coverage for tirzepatide will likely be a barrier to patient use, especially before tirzepatide has been officially recognized as a standard of care in professional guidelines. 2”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [2]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“33% with metformin as initial pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (33).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Research works printed but not linked: 1
- Dicembrini, Impact of technology on glycemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion, Diabetes Obes Metab
Cited by
Items 801–846 of 846
Peprah, E. B., Jahan, Y., Danso‐Appiah, A., Abdul-Samed, A.-B., Mirzoev, T. N., Antwi, E., Balabanova, D., & Agyepong, I. A. (2024) · Figshare · doi:10.6084/m9.figshare.26945541
Paolisso, P., Foà, A., Bergamaschi, L., Angeli, F., Fabrizio, M., Donati, F., Toniolo, S., Chiti, C., Rinaldi, A., Stefanizzi, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16680270
Sinning, C., Makarova, N., Völzke, H., Schnabel, R. B., Ojeda, F., Dörr, M., Felix, S. B., Koenig, W., Peters, A., Rathmann, W., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17021013
Ling, S., Sweeting, M., Zaccardi, F., Adlam, D., & Kadam, U. T. (2022) · Figshare · doi:10.6084/m9.figshare.21291844
Peprah, E. B., Jahan, Y., Danso‐Appiah, A., Abdul-Samed, A.-B., Mirzoev, T. N., Antwi, E., Balabanova, D., & Agyepong, I. A. (2024) · Figshare · doi:10.6084/m9.figshare.26945538
Pei, J., Wang, X., Pei, Z., & Hu, X. (2023) · Figshare · doi:10.6084/m9.figshare.24452462
Tokutsu, A., Okada, Y., Torimoto, K., & Tanaka, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14429219
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26620396
Franc, S., Reznik, Y., Amadou, C., Penfornis, A., Schaepelynck, P., Hanaire, H. P., Delemer, B., Tallec, C. L., Beltrand, J., Jeandidier, N., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02780-5
Exploring the Anti‐Diabetic Potential of Anthocyanins: From Biochemical Pathways to Human Trials
Panchal, L., Yadav, S., Kumar, A., Kaur, T., Bawa, Y., Rustagi, S., & Mehra, R. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70033 · Cited by 1
“However, both types of diabetes may cause several complications, such as diabetic ketoacidosis, hyperosmolar hyperglycemia, nonketotic coma, diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy [7–9].”
The prevalence of dry eye disease among patients with diabetes in Malawi: A hospital based study
Ogbonna, G. O., Phiri, E. C., Ezinne, N. E., Ehigbor, R., Chikohza, M., Moyo, G., Kyei, S., & Kwarteng, M. A. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01622-1
Meng, X., Liu, Z., Zhao, Z., Chen, L., Li, S., Qi, S., Guo, R., Zhang, X., Meng, F., Zhang, H., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-01313
Jamali, M., Dabbaghmanesh, M. H., KraskianMujemnari, A., & Hidaji, M. B. (2026) · Shiraz E-Medical Journal · doi:10.5812/semj-161107
Zhou, L., Wu, C., Wang, C., Yu, X., Qu, D., Yang, Y., Xu, X., Liu, J., Zhu, Q., Liao, X., et al. (2026) · Endocrine · doi:10.1007/s12020-025-04509-z · Cited by 1
“CGM is one of the great advances in diabetes technology, which not only records glucose data, but also provides more meaningful indicators of diabetes management than HbA1c, such as TIR, CV, GMI, MAGE [ 20, 21].”
Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea
Kim, J.-T., Lee, J. S., Kim, H., Kim, B. J., Kang, J., Lee, K., Park, J., Kang, K., Lee, S. J., Kim, J. G., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046592
“20 “Well-controlled dyslipidemia” was defined as prior statin use with an admission LDL-C 100 mg/dL. 21 “Well-controlled AF” was defined as prior use of oral anticoagulants before stroke.”
Naseer, M., Ullah, F., & Zhao, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40379-8.00015-6
Azizi, R., Foroozanfar, Z., Mehrabbeik, A., & Namiranian, N. (2026) · Intern J Endocrinol Metab · doi:10.5812/ijem-166802
Rydberg, M., Eeg‐Olofsson, K., & Arner, M. (2026) · Hand · doi:10.1177/15589447261424448
Zhang, F., & Zhong, Y. (2026) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2026.100313
Comparability of venous versus capillary hemoglobin A1c measurements
Yunir, E., Wafa, S., Indrasari, N. D., Iswati, E., Christabel, E. V., Widiyanti, D., Wisnu, W., Kurniawan, F., Amalina, N., Pradnjaparamita, T., et al. (2026) · Diabetology International · doi:10.1007/s13340-026-00889-3
“ADA now includes hemoglobin A1c level as a parameter for evaluating metabolic control in T2D patients, using a venous blood sample measured in the laboratory as the gold standard [6].”
Chen, L., Liu, H., Chen, Y., Xiao, Q., Huang, Z., Li, Z., Zhang, X., Fan, X., Xiao, M., Li, X., et al. (2026) · Food & Function · doi:10.1039/d5fo04996b
Intervención educativa para el automanejo de la diabetes mellitus tipo 2 en adultos mexicanos
Santamaría, Y. R., Gallegos-Cabriales, E. C., Gutiérrez-Valverde, J. M., G, M. C., Juárez-Medina, L. L., & Tochihuitl, M. M. (2026) · Enfermería Universitaria · doi:10.22201/feno.23958421e.2023.3.1340
Bondzie, E. P. K., Adjei-Banuah, N. Y., Afun, N. E. E., Peprah, E. B., Jahan, Y., Mirzoev, T. N., Balabanova, D., & Agyepong, I. A. (2026) · medRxiv · doi:10.64898/2026.05.16.26353078
Teklay, G., Tafere, H., & Niriayo, Y. L. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02332-9
“The recommended HbA1c target for diabetes control is ≤ 7.0% (≤ 53 mmol/mol) [3, 7].”
InfluentialLi, W., Qin, L., Zhu, G., Lili, C., Rong, G., & Liping, W. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1805855
Al-janabi, D. R. A., Talib, R. M., Shakir, A. H., Hussain, N. N. M., Rashied, H. M., Turki, T. G., Salih, H. A., Khudhur, M. S., Muhail, Q. A. M., Amery, M. A. M. A., et al. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.31s.18
“In order to lower the risk of long-term microvascular and macrovascular problems and to enhance overall clinical outcomes, it is imperative that newly diagnosed patients achieve early glycemic control (4).”
Sonmez, A., Haymana, C., Demirci, İ., Çetinarslan, B., Gönen, M. S., Akbaş, E. M., Yalın, G. Y., Avcı, U., Taşçı, İ., Salman, S., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109348
Name, M. A. V., Sherr, J. L., Bauza, C., Buckingham, B. A., Forlenza, G. P., Neyman, A., Beck, R. W., Bailey, R. J., Kollman, C., Beasley, S., et al. (2026) · Hormone Research in Paediatrics · doi:10.1159/000552649
Amirthalingam, P., Alarawi, F., Alagwar, L. M. J., Alatawi, M., Alzahrani, M. S. A., Albalwi, A. O. A., Alrashidi, A., Hamdan, A. M. E., Alqifari, S. F., Alshareef, H. M., et al. (2026) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s610579
Kinetics of Hypoglycemia in Diabetes Patients Informs Development of New Modes of Glucagon TherapyPreprint
Li, J., Byrne, C., Liang, J., Lee, S., Lyhne, M. K., Meng, A., Ling, S. R., Li, S., Lopes, A., Khosravi, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.05.729994
“Thus, hypoglycemia remains the most serious acute complication among patients with diabetes and often limits the use of intensive insulin therapy resulting in an increased risk of long-term diabetic complications 1,2 .”
A Patient- and Function-Centric Model/Approach for Hypoglycemia Management in Older Adults
Alagiakrishnan, K., Mereu, L., Rahim, G., Ghosh, M., & Vu, A. (2026) · Geriatrics · doi:10.3390/geriatrics11050118
Li, M., Wang, X. J., Ma, G., Meng, Y., Fang, H., & Miao, Y. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1842877
“Levels of 2hPG and HbA1c reflect acute postprandial glucose fluctuations and chronic glycemic exposure, respectively (45).”
Zhang, H., & Deng, L. (2026) · Archives of Medical Science · doi:10.5114/aoms/221240
Comparison of Two Ion-Exchange HPLC Methods for HbA1c Quantitation
Latzig, D. L., Zwiefelhofer, P., & Gunsolus, I. L. (2026) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfag112
Manninen, S. M., Lamidi, M., Wang, Z., Lavikainen, P., Wikström, K., Storvik, S. D., Kivinen, P. K., Rautiainen, P., & Laatikainen, T. K. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113515
Dai, D., Chen, S., Li, Q., Chu, C., Li, F., Maimati, Y., Wu, X., Zhang, W., Chen, Q., Wang, Y., et al. (2026) · Diabetes and Vascular Disease Research · doi:10.1177/14791641261484961
Güler, B. Y., Demirci, İ., Haymana, C., Akbay, E., Evren, B., Dizdar, O. S., Demir, O., Ağbaht, K., Taşçı, İ., Ersoy, C., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04676-7
“Treatment goals were set as HbA1c 7% ( 53 mmol/mol), home blood pressure 135/85 mmHg or office measure - ments 140/90 mmHg, and LDL-C targets of 55, 70, or 100 mg/dL depending on clinical risk and complica - tion status [16, 19 ].”
Liu, T., Ni, Y., Wang, P., & Wu, J. (2026) · PeerJ · doi:10.7717/peerj.21743
“The inclusion criteria were as follows: fulfilled the T2DM international criteria (American Diabetes Association) ( American Diabetes Association, 2021 ).”
Dental anxiety and fear: A potential barrier to periodontal health
Lai, C. W. M., Chew, R. J. J., Seah, F., Lee, M. H., Fu, J., Yip, J. W., Tan, K. S., Toh, S. A., Preshaw, P. M., & Goh, C. E. (2026) · Journal of Dentistry · doi:10.1016/j.jdent.2026.107072
Madhusikta, S., Nayak, S., & Mishra, A. (2026) · Cureus · doi:10.7759/cureus.117580
“Self-care interventions include evidence-based, quality drugs, devices, diagnostics, and/or digital products that can be provided fully or partially outside of formal health services and can be used with or without a health worker [17].”
Oral microbial nitrate metabolism is associated with lower prevalence of prediabetes
Zhao, S., Haryono, M. A. S., Lai, C. W. M., Seah, F., Tang, Y. L., Lim, M., Febriana, E., Lee, M. H., Tan, K. W., Fu, J. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103092
Joubert, N., Adams, L., Seelig, H., Gardiner, E. C., van de Venter, R., Degen, J., Dolley, D., Müller, I., Nqweniso, S., Probst-Hensch, N., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1794604
Liu, Q., Tao, J., Wang, H., Wang, C., Nie, Y., Li, Z., Shen, Z., Xu, X., Guo, H., Yang, B., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10958859/v1
Rahiman, S. A., Sanjeev, G., Prathap, G., Rajasekharan, G., & Chandrasekharan, R. (2026) · Cureus · doi:10.7759/cureus.117718
“Patients were classified as having uncontrolled T2DM (HbA1c >7%, n = 34) or controlled T2DM (HbA1c ≤7%, n = 34) based on the 2021 American Diabetes Association glycemic target guidelines [14].”
Ballesta, S., Pedro‐Botet, J., Climent, E., Fernández‐Veledo, S., Gaja, R., Garrido, A., Vendrell, J. J., Sánchez, J., Fernández-Miró, M., Chillarón, J. J., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag422
Benhamou, P., Vesin, A., Reynaud, L., Roux‐Mallouf, T. L., & Chatel, B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71452
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S73-S84
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4236126199
- Cited by
- 847
- References
- 118
- Citations by year
- 2026: 43 · 2025: 80 · 2024: 115 · 2023: 156 · 2022: 265 · 2021: 187 · 2020: 1
- FWCI
- 23.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic targets, diabetes management, clinical guidelines, quality of care, level of evidence, treatment goals
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.